Edition:
United States

OncoGenex Pharmaceuticals Inc (OGXI.OQ)

OGXI.OQ on NASDAQ Stock Exchange Capital Market

0.45USD
4:00pm EDT
Change (% chg)

$-0.02 (-3.84%)
Prev Close
$0.47
Open
$0.48
Day's High
$0.48
Day's Low
$0.45
Volume
7,879
Avg. Vol
61,069
52-wk High
$0.98
52-wk Low
$0.33

Latest Key Developments (Source: Significant Developments)

Oncogenex Pharmaceuticals reports Q1 loss per share $0.11
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Oncogenex Pharmaceuticals Inc :Oncogenex Pharmaceuticals Inc. reports financial results for first quarter 2017.Oncogenex Pharmaceuticals Inc says revenue for three months ended March 31, 2017 decreased to zero from $2.9 million for three months ended march 31, 2016.Oncogenex Pharmaceuticals Inc - qtrly loss per share $0.11.  Full Article

Oncogenex Pharma and Achieve Life Science announce strategic collaboration with National Institutes of Health
Wednesday, 1 Mar 2017 09:00am EST 

Oncogenex Pharmaceuticals Inc : Oncogenex Pharma says Achieve Life Science and co announce strategic collaboration with National Institutes of Health to advance development of cytisine . Oncogenex Pharmaceuticals Inc says results of initial study are expected in second-quarter of 2017 .Oncogenex Pharmaceuticals Inc says multiple key cytisine development and regulatory milestones expected in 2017.  Full Article

Oncogenex Pharma believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for next 12 months
Thursday, 23 Feb 2017 09:00am EST 

Oncogenex Pharmaceuticals Inc : Oncogenex pharma - believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for at least next 12 months . Oncogenex pharmaceuticals inc - revenue for q4 was zero .Oncogenex pharmaceuticals inc - net loss for q4 and year ended december 31, 2016 was $5.8 million and $20.1 million, respectively.  Full Article

Oncogenex Pharmaceuticals says clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated
Tuesday, 21 Feb 2017 09:00am EST 

Oncogenex Pharmaceuticals Inc : Oncogenex Pharmaceuticals, Inc. announces phase 2 apatorsen data for two clinical trials presented at the American Society Of Clinical Oncology (asco) 2017 genitourinary cancers symposium .Oncogenex Pharmaceuticals Inc- clinical data from trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated.  Full Article

Oncogenex Pharmaceuticals and Achieve Life Science announce definitive merger agreement
Thursday, 5 Jan 2017 04:30pm EST 

Oncogenex Pharmaceuticals Inc : Oncogenex Pharmaceuticals Inc and Achieve Life Science, Inc announce definitive merger agreement . Oncogenex - upon completion of proposed merger, achieve's equity holders are expected to own 75 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - combined company's executive management team will be led by Rick Stewart, chairman of Achieve . Oncogenex Pharmaceuticals - expected to distribute to its stockholders contingent value rights (CVRS) for 80 pct of any net proceeds of certain payments . Oncogenex Pharmaceuticals Inc - board of directors of combined company is expected to consist of seven members . Following completion of merger, Oncogenex Pharmaceuticals Inc ill be renamed Achieve Life Sciences Inc . Oncogenex - after completion, current stockholders of oncogenex are expected to own remaining 25 pct of combined company's outstanding shares . Oncogenex Pharmaceuticals Inc - "efforts will continue to establish a strategic partnership to further development of apatorsen" .Oncogenex Pharmaceuticals Inc - transaction has been approved unanimously by boards of directors of both companies.  Full Article

Oncogenex Pharmaceuticals says committed to further reduction in workforce
Thursday, 17 Nov 2016 04:17pm EST 

Oncogenex Pharmaceuticals Inc : Will eliminate 5 positions and estimates that will incur about $750,000 in cash expenditures as a result . On Nov 14, co committed to further reduction in workforce in order to preserve company's resources .Expects workforce reduction to be substantially complete in Q4 of 2016 - SEC filing.  Full Article

Oncogenex Pharmaceuticals reports Q3 loss per share $0.12
Thursday, 10 Nov 2016 04:01pm EST 

Oncogenex Pharmaceuticals Inc - : Oncogenex Pharmaceuticals Inc reports financial results for third quarter 2016 . Qtrly loss per share $0.12 .Qtrly revenue $3.8 million versus $3.1 million.  Full Article

Oncogenex's Phase 3 trial of Custirsen in men did not meet primary endpoint
Tuesday, 16 Aug 2016 07:00am EDT 

Oncogenex Pharmaceuticals Inc : Oncogenex announces results from the phase 3 affinity trial of custirsen in men with metastatic castrate-resistant prostate cancer . To initiate discussions with U.S. Food and drug administration to evaluate options related to an early analysis of phase 3 enspirit trial . Trial did not meet primary endpoint . Adverse events were consistent with those observed in previous trials of custirsen in metastatic crpc .Engaged MTS Health Partners, Lp as its advisor to assist with exploration of strategic alternatives.  Full Article

Oncogenex Pharma Q2 revenue $2.1 million vs est $1.2 million
Thursday, 4 Aug 2016 04:01pm EDT 

Oncogenex Pharmaceuticals Inc : Oncogenex pharmaceuticals, inc. Reports financial results for second quarter 2016 . Q2 revenue $2.1 million .Q2 revenue view $1.2 million -- Thomson Reuters I/B/E/S.  Full Article

Oncogenex Pharmaceuticals qtrly loss per share $0.12
Thursday, 12 May 2016 04:15pm EDT 

Oncogenex Pharmaceuticals Inc : Qtrly loss per share $0.12 . Oncogenex pharmaceuticals, inc. Reports financial results for first quarter 2016 . Q1 revenue $2.9 million .Q1 revenue view $4.1 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Oncogenex Pharmaceuticals reports Q1 loss per share $0.11

* Oncogenex Pharmaceuticals Inc. reports financial results for first quarter 2017